Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics reported higher collaboration revenue and a wider loss for the quarter ended March 31, 2026. Collaboration revenue rose to $34.4 million, driven by recognition of deferred revenue from its Gilead CDK2 partnership, while the company recorded a net loss of $69.2 million and basic and diluted net loss per share of $0.71.
Total operating expenses increased to $118.5 million, led by research and development spending of $98.2 million as multiple programs advance. Kymera ended the quarter with $1.55 billion in cash, cash equivalents and marketable securities and $1.54 billion of stockholders’ equity, providing substantial funding for its clinical-stage targeted protein degradation pipeline.
The company’s Sanofi IRAK4 collaboration did not contribute revenue this quarter after prior milestones, while Gilead collaboration revenue fully relieved related deferred revenue. After quarter-end, Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone expected to be recognized as second-quarter 2026 revenue.
Kymera Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger collaboration revenue. Collaboration revenue was $34.4 million, up from $22.1 million a year earlier, driven by its partnership with Gilead Sciences.
Research and development expenses rose to $98.2 million and general and administrative expenses to $20.4 million, leading to a net loss of $69.2 million, compared with $65.6 million in the prior-year quarter. Kymera ended March 31, 2026 with $1.55 billion in cash, cash equivalents and investments and expects this balance to fund operations into 2029 while advancing KT-621, KT-579 and partnered programs including KT-200 and KT-485/SAR447971.
Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock. On April 29, 2026, he exercised stock options to acquire 30,000 shares at $2.08 per share and then sold 30,000 shares of common stock in open-market trades.
The sales were split into blocks of 936, 12,059, and 17,005 shares at weighted average prices of about $82.45, $81.70, and $80.74. According to the filing, these trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Mainolfi directly held 666,195 shares of Kymera common stock.
Kymera Therapeutics is asking shareholders to vote at its virtual 2026 annual meeting on June 24, 2026. Holders of 82,257,588 common shares as of April 27, 2026 may participate online.
Shareholders will elect four Class III directors to serve until 2029, cast a non-binding advisory “Say‑on‑Pay” vote on executive compensation, and vote on ratifying Ernst & Young LLP as independent auditor for 2026. The board recommends voting “FOR” all three proposals.
The proxy outlines a staggered board structure, committee independence, and a clawback policy, and describes Kymera’s performance-based pay philosophy, including a 125% corporate bonus funding factor for 2025 tied to pipeline progress, strategic partnerships, and a year‑end cash balance of about $1.6 billion.
Kymera Therapeutics director Bruce Booth reported option exercises and related share sales in Kymera Therapeutics, Inc. common stock. On April 22, 2026 he exercised options for 259 shares at $20.00 per share and 5,641 shares at $14.18 per share, then sold 5,900 shares in open‑market transactions at a weighted average price of about $89.96 per share, leaving no directly owned shares.
Entities associated with Atlas Venture made additional small sales of 12 and 88 shares at $90.08 per share. After these trades, Atlas Venture Fund X, L.P. held 674,944 shares and Atlas Venture Opportunity Fund I, L.P. held 3,899,829 shares, with Booth disclaiming Section 16 beneficial ownership except to any pecuniary interest. The filing notes these sales were made under pre‑arranged Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale. On April 22, 2026, he exercised stock options for a total of 300 shares of common stock at exercise prices of $43.50 and $30.17 per share, then made an open-market sale of 300 shares at $90.00 per share. After these transactions, he directly held 61,202 shares of Kymera common stock. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating they were scheduled in advance rather than timed discretionarily.
KYMR notice: Section 144 filings report proposed sales of Common Stock by several holders. Examples include Atlas Venture Fund X, L.P. proposing 71,814 shares on 03/02/2026 for $6,472,674.74 and other smaller dispositions in March–April 2026.
KYMR submitted Form 144 notices reporting multiple proposed sales of Common Stock by affiliated holders. The excerpt lists several transactions, including Atlas Venture Fund X, L.P.'s proposed sale of 71,814 shares on 03/02/2026 and smaller sales by Atlas Venture Opportunity Fund I and Bruce Booth on 03/02/2026, 04/14/2026, and 04/15/2026.
KYMR affiliate reported proposed and recent sales of Common Stock. The filing lists an exercise of 300 shares on 04/22/2026 and multiple 10b5-1 sales between 03/02/2026 and 04/15/2026, including transactions of 91,250 shares for $7,063,733.26.